Cullinan Therapeutics, Inc. logo CGEM - Cullinan Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 8
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $32.20 DETAILS
HIGH: $39.00
LOW: $27.00
MEDIAN: $30.00
CONSENSUS: $32.20
UPSIDE: 45.77%

Stock News

Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset

Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset

Cullinan Therapeutics offers a unique, multi-asset portfolio with near-, mid-, and long-term value drivers, reducing reliance on external funding. Zipalertinib's positive Phase 3 results and upcoming regulatory milestones provide a potential funding bridge for advancing CGEM's autoimmune and oncology platforms. CLN-049's accelerated regulatory path in AML and CLN-978's promising early autoimmune data position CGEM for multiple commercialization opportunities.

Aug 26, 2026 01:41 AM • seekingalpha.com
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLC PRINCETON, N.J., CAMBRIDGE, Mass., August 19, 2026 — Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been selected for presentation in the Presidential Symposium 2 at

Aug 19, 2026 08:03 AM • businesswire.com
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced positive feedback from the U.S. Food and Drug Administration (FDA) following an End-of-Phase 1 (EOP1) meeting for CLN-049, a FLT3xCD3 T cell engager being evaluated in patients with acute myeloid leukemia (AML).

Jul 28, 2026 03:00 AM • globenewswire.com
Cullinan Therapeutics: Heading Toward Paydirt

Cullinan Therapeutics: Heading Toward Paydirt

Cullinan Therapeutics remains a compelling buy as zipalertinib approaches a key FDA decision for EGFR exon 20 insertion NSCLC. Zipalertinib demonstrates promising efficacy, including CNS activity and responses post-amivantamab, with pivotal phase 3 REZILIENT3 data expected later this year. CGEM's diversified pipeline in oncology and immunology, strong cash reserves, and operational runway into 2029 support continued optimism.

Jun 11, 2026 07:41 AM • seekingalpha.com
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 Deep, dose-dependent B cell depletion observed in peripheral blood and tissue Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinan's Immunology Day on June 10 CAMBRIDGE, Mass.

Jun 06, 2026 01:15 AM • globenewswire.com
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies  Initial data from the first multi-dose cohort of RA study to be presented Initial data from the first multi-dose cohort of velinotamig study also to be shared Leading key opinion leaders Dr. Ricardo Grieshaber-Bouyer and Dr. John Tesser to share clinical perspectives The Company will host the in-person event for analysts and institutional investors on Wednesday, June 10, starting at 8:30 a.m. ET in New York City CAMBRIDGE, Mass.

May 26, 2026 03:00 AM • globenewswire.com
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc.  (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that initial clinical data from two ongoing Phase 1 studies evaluating CLN-978, a subcutaneously administered CD19xCD3 T cell engager, will be presented at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology being held June 3-6, 2026 in London, United Kingdom.

May 18, 2026 01:00 PM • globenewswire.com
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026  Zipalertinib NDA for relapsed EGFR ex20ins NSCLC accepted by U.S. FDA; PDUFA target action date of February 27, 2027 Cash and investments of $393.3 million as of March 31, 2026; runway into 2029 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights and announced its financial results for the first quarter ended March 31, 2026.

May 07, 2026 03:00 AM • globenewswire.com
Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst

Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst

Cullinan Therapeutics's Zipalertinib NDA has been accepted, making its February 27, 2027, PDUFA date their clearest near-term catalyst. Zipalertinib targets EGFR exon 20 insertion NSCLC, a niche but still meaningful demographic that could expand over time with more trials for new indications. CGEM's CLN-978, Velinotamig, and CLN-049 add other interesting assets in their pipeline across autoimmune disease and AML.

Apr 30, 2026 09:53 AM • seekingalpha.com
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for zipalertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations whose disease has progressed.

Apr 28, 2026 03:00 AM • businesswire.com
Cullinan Therapeutics (NASDAQ:CGEM) versus Genprex (NASDAQ:GNPX) Head to Head Comparison

Cullinan Therapeutics (NASDAQ:CGEM) versus Genprex (NASDAQ:GNPX) Head to Head Comparison

Genprex (NASDAQ: GNPX - Get Free Report) and Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations. Analyst Recommendations This is a breakdown of recent

Mar 27, 2026 09:28 PM • defenseworld.net
Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data

Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data

Cullinan Therapeutics (NASDAQ: CGEM) outlined a milestone-heavy roadmap during a presentation at Leerink Partners' Annual Healthcare Conference in Miami, with management emphasizing 2026 as a potentially "defining year" driven by multiple clinical readouts across its pipeline. Chief Executive Officer Nadim and Chief Medical Officer Jeff highlighted two "high-priority" T-cell engager (TCE) programs-CLN-978 in autoimmune diseases and

Mar 13, 2026 09:13 PM • defenseworld.net
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline study completed with top-line results available by year-end 2026 Cash and investments of $439.0 million as of December 31, 2025; runway into 2029 CAMBRIDGE, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2025.

Mar 10, 2026 03:00 AM • globenewswire.com

Price Targets